Chronotypes in middle-aged women with polycystic ovary syndrome: A population-based study
- PMID: 39422521
- PMCID: PMC11610004
- DOI: 10.1111/aogs.14991
Chronotypes in middle-aged women with polycystic ovary syndrome: A population-based study
Abstract
Introduction: Circadian rhythm disruption has been associated with the risk of polycystic ovary syndrome (PCOS), as the evening chronotype (EC) shares several traits with PCOS, including metabolic disorders, cardiovascular diseases, and psychiatric disorders. It has been suggested that the biological clock could be targeted with new, preventive, and therapeutic strategies for PCOS in women with biorhythm disorders. We evaluated inner circadian rhythmicity in middle-aged women with PCOS in a population-based setting, focusing on whether women with PCOS and an EC have a specific subtype in relation to their clinical characteristics.
Material and methods: The data derived from the Northern Finland Birth Cohort, a population-based longitudinal birth cohort of 12 058 individuals born in 1966. We compared the circadian phenotype between 314 women with PCOS (according to the Rotterdam criteria) and 1248 women without PCOS at age 46 years using the validated Finnish shortened 6-item Morningness-Eveningness Questionnaire (sMEQ) and the single-item self-assessed morningness-eveningness question.
Results: PCOS was not associated with the EC by the sMEQ (p = 0.495) or self-assessment (p = 0.303). The self-assessed morningness-eveningness values differed from the sMEQ chronotype distribution (p < 0.001), nevertheless, the most frequent chronotype was the intermediate chronotype (IC) determined by both chronotyping methods (sMEQ PCOS 47.7% vs. 45.2% non-PCOS; self-assessment PCOS 66.5% vs. 68.4% non-PCOS). The hyperandrogenic PCOS phenotypes A-C did not differ from the non-hyperandrogenic phenotype D as for the chronotype (p = 0.271). The EC was associated in both groups with depressive and anxiety symptoms (PCOS p = 0.012, non-PCOS p < 0.001) and the use of sleep medication (PCOS p = 0.017, non-PCOS p < 0.001).
Conclusions: The EC was not over-represented in middle-aged women with PCOS or in the hyperandrogenic PCOS phenotypes A-C in our study. This does not support the need for chronotyping in the comprehensive assessment of women with PCOS. However, as chronotypes tend to change with aging, cross-sectional studies in different age groups are warranted to draw conclusions on the role of chronotypes in PCOS and the associated metabolic risks.
Keywords: MEQ; PCOS; chronotype; circadian rhythm; morningness‐eveningness; polycystic ovary syndrome.
© 2024 The Author(s). Acta Obstetricia et Gynecologica Scandinavica published by John Wiley & Sons Ltd on behalf of Nordic Federation of Societies of Obstetrics and Gynecology (NFOG).
Conflict of interest statement
The authors declare that they have no conflicts of interest.
Figures


Similar articles
-
Genetic variants for morningness in relation to habitual sleep-wake behavior and diurnal preference in a population-based sample of 17,243 adults.Sleep Med. 2021 Apr;80:322-332. doi: 10.1016/j.sleep.2021.01.054. Epub 2021 Jan 30. Sleep Med. 2021. PMID: 33631501
-
Chronotypes in patients with nonseasonal depressive disorder: Distribution, stability and association with clinical variables.Chronobiol Int. 2015;32(10):1343-51. doi: 10.3109/07420528.2015.1091353. Epub 2015 Nov 5. Chronobiol Int. 2015. PMID: 26540575
-
Chronotype influences activity circadian rhythm and sleep: differences in sleep quality between weekdays and weekend.Chronobiol Int. 2015 Apr;32(3):405-15. doi: 10.3109/07420528.2014.986273. Epub 2014 Dec 3. Chronobiol Int. 2015. PMID: 25469597
-
Sleep timing, chronotype and social jetlag: Impact on cognitive abilities and psychiatric disorders.Biochem Pharmacol. 2021 Sep;191:114438. doi: 10.1016/j.bcp.2021.114438. Epub 2021 Feb 2. Biochem Pharmacol. 2021. PMID: 33545116 Review.
-
Gender differences in chronotype diminish with age: a meta-analysis based on morningness/chronotype questionnaires.Chronobiol Int. 2019 Jul;36(7):888-905. doi: 10.1080/07420528.2019.1585867. Epub 2019 May 9. Chronobiol Int. 2019. PMID: 31070061
References
-
- Teede HJ, Tay CT, Laven JJE, et al. Recommendations from the 2023 international evidence‐based guideline for the assessment and management of polycystic ovary syndrome. Eur J Endocrinol. 2023;189:G43‐G64. - PubMed
-
- Lizneva D, Suturina L, Walker W, Brakta S, Gavrilova‐Jordan L, Azziz R. Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertil Steril. 2016;106:6‐15. - PubMed
-
- Cinar N, Kizilarslanoglu MC, Harmanci A, et al. Depression, anxiety, and cardiometabolic risk in polycystic ovary syndrome. Hum Reprod. 2011;26:3339‐3345. - PubMed
-
- Pinola P, Puukka K, Piltonen TT, et al. Normo‐ and hyperandrogenic women with polycystic ovary syndrome exhibit an adverse metabolic profile through life. Fertil Steril. 2017;107:788‐795.e2. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical